RCI
TVRD

Ridgeback Capital Investments’s Tvardi Therapeutics TVRD Stock Holding History

Ridgeback Capital Investments’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,282
Closed -$10.5M – 1
2015
Q4 		$10.5M Buy
+17,282
New +$9.49M 45.13% 1

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ridgeback Capital Investments's TVRD Position: Q1 2016 in Review

Ridgeback Capital Investments sold out of Tvardi Therapeutics (TVRD) in Q1 2016, closing a stake of 17,282 shares — an estimated $10.5M sold.

Ridgeback Capital Investments first reported a position in TVRD in Q4 2015 and held it in 1 quarter. The position peaked at $10.5M in Q4 2015. 93 funds tracked by Wall St. Rank hold TVRD as of Q1 2016.

  • Ridgeback Capital Investments reported no remaining Tvardi Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Ridgeback Capital Investments sold 17,282 Tvardi Therapeutics shares in Q1 2016, an estimated $10.5M.
  • Ridgeback Capital Investments first reported a position in Tvardi Therapeutics in Q4 2015 and held it in 1 quarter.
  • Ridgeback Capital Investments's Tvardi Therapeutics position peaked at $10.5M in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2016.

Based on Ridgeback Capital Investments's 13F filing for Q1 2016.